In English | En español
¿Preguntas sobre el cáncer? 1-800-422-6237

Linfoma de Hodgkin infantil: Tratamiento (PDQ®)

  • Actualización: 18 de abril de 2014

Cuadro 2. Criterios utilizados para la clasificación de grupos de riesgo en los ensayos clínicos sobre linfoma de Hodgkin infantila

Ensayo Riesgo bajo Riesgo intermedio Riesgo alto 
Children's Oncology Group
AHOD0031 [20]IA voluminosa o E; IB; IIA voluminosa o E; IIB; IIIA, IVA
AHOD0431 [21]IA, IIA sin masa tumoral
AHOD0831 IIIB, IVB
C5942 [22]IA, IB, IIA sin masa tumoral, sin ganglios hiliares y <4 sitiosIA, IB, IIA voluminosas, ganglios hiliares o ≥4 sitios; IIIIV
C59704 [23]IIB/IIIB voluminosa, IV
P9425/P9426 [24]IA, IIA sin masa tumoralIB, IIA, IIIA1 voluminosas; IIIA2IIB, IIIB, IV
German Multicenter/Euronet
GPOH-HD 95; GPOH-HD 2002; PHL-C1 [4,25,26]1A/B, IIAIEA/B;IIEA; IIB; IIIAIIEB; IIIEA/B; IIIB; IV
Stanford/St. Jude/Dana-Farber Cancer Institute Consortium
HOD05 IB, IIIA, IA/IIA con E, ≥3 sitios o con gran masa tumoral
HOD08 IA, IIA sin gran masa tumoral, E y <3 sitios
HOD99 IIB, IIIB, IV

E = extralinfático.
aAdaptado de Kelly.[19]

Bibliografía

  1. Mauz-Körholz C, Hasenclever D, Dörffel W, et al.: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28 (23): 3680-6, 2010.  [PUBMED Abstract]

  2. Kelly KM: Management of children with high-risk Hodgkin lymphoma. Br J Haematol 157 (1): 3-13, 2012.  [PUBMED Abstract]

  3. Friedman DI, Wolden S, Constine L, et al.: AHOD0031: A phase III study of dose intensive therapy for intermediate risk Hodgkin lymphoma: a report from the Children’s Oncology Group. [Abstract] Blood 116 (22): A-766, 2010. 

  4. Keller FG, Nachman J, Constine L: A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL). [Abstract] Blood 116 (21): A-767, 2010. 

  5. Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (18): 3765-71, 2002.  [PUBMED Abstract]

  6. Kelly KM, Sposto R, Hutchinson R, et al.: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117 (9): 2596-603, 2011.  [PUBMED Abstract]

  7. Schwartz CL, Constine LS, Villaluna D, et al.: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114 (10): 2051-9, 2009.  [PUBMED Abstract]

  8. Schellong G, Pötter R, Brämswig J, et al.: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17 (12): 3736-44, 1999.  [PUBMED Abstract]

  9. Dörffel W, Lüders H, Rühl U, et al.: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215 (3): 139-45, 2003 May-Jun.  [PUBMED Abstract]